Table 4.
Biomarker | DEC n = 58 | EFC n = 37 | VFC n = 23 | |||
---|---|---|---|---|---|---|
pRR (%) | p** | pRR (%) | p** | pRR (%) | p** | |
ER | ||||||
negative | 67.9 | 0.000** | 50.0 | 0.003** | 57.1 | 0.040** |
positive | 20.0 | 3.7 | 11.1 | |||
PR | ||||||
negative | 58.1 | 0.014** | 26.3 | 0.180 | 58.3 | 0.089 |
positive | 25.9 | 5.6 | 18.2 | |||
HER2 | ||||||
negative | 16.7 | 0.001** | 25.0 | 0.371 | 55.6 | 0.383 |
positive | 61.8 | 16.2 | 28.6 | |||
P-gp | ||||||
negative | 38.6 | 0.223 | 13.3 | 0.315 | 42.1 | 1.000 |
positive | 57.1 | 28.6 | 25.0 | |||
MRP | ||||||
negative | 32.0 | 0.137 | 7.7 | 0.394 | 22.2 | 0.228 |
positive | 51.5 | 20.8 | 50.0 | |||
GST-pi | ||||||
negative | 42.9 | 0.963 | 8.7 | 0.173 | 30.8 | 0.417 |
positive | 43.5 | 28.6 | 50.0 | |||
Topo-II | ||||||
negative | 26.1 | 0.034** | 6.7 | 0.368 | 42.9 | 1.000 |
positive | 54.3 | 22.7 | 37.5 |
# pRR: pathologic response rate
* D docetaxel, E epirubicin, C cyclophosphamide, F 5-Fluorouracil, V vinorelbine or vincristine
**p < 0.05 is considered statistically significant